Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of FUSION™ Vascular Graft for Above Knee Targets

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* No known malignant disease~* Patient was willing and able to have follow-up visits and examinations~* Peripheral arterial occlusive disease (PAOD) requiring treatment of the femoral artery; Fontaine stage IIb, III and IV with dry peripheral gangrene, and suitable for surgery~* Patient was not participating in other clinical trials that would conflict with this protocol~* Patient agreed to the study provisions and provided written informed consent~Exclusion Criteria:~* Urgent or emergent surgery of any kind~* Documented acute or suspected systemic infection~* Life expectancy of less than one year~* Patients who had a minor or major stroke within 6 weeks of the procedure or who had evidence of prior massive stroke~* Patients who had experienced a myocardial infarction within 6 weeks prior to the procedure or had unstable angina pectoris~* Severe chronic renal insufficiency or undergoing hemodialysis~* Patients treated with coumadin (warfarin) that had not been stopped within 72 before enrollment~* Medical conditions requiring oral anticoagulation~* Antiplatelet therapy with clopidogrel or dual antiplatelet as well as any other antithrombotic medication within 7 days prior to scheduled bypass surgery except unfractionated heparin or aspirin~* International normalized ratio (INR) \> 2.0~* Known hypersensitivity to heparin~* Patient not tolerating aspirin~* Previous history of bypass surgery in the target limb~* Patient with category 6 ischemia (tissue loss)~* Acute limb ischemia of any grade (0-3)~* Patient with no outflow beyond the popliteal artery~* Pregnant or may become pregnant during the course of the study~* Uncontrolled arterial hypertension (BP \> 200 mmHg) at 2 successive readings~* Anaemia (hemoglobin \< 8 g/ml)~* Thrombocytopenia \< 50 g/L~* Active bleeding according to clinical judgment~* Infected wet gangrene of any size and location at the target limb~* Compromised arterial flow~* Patient unwilling or unable to comply with follow-up requirements

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- FUSION Vascular Graft (Type: EXPERIMENTAL): All subjects who received a FUSION Vascular Graft at the baseline implant procedure.

Based on this trial design, predict the completion outcome and termination type (if applicable).